Global healthcare solutions company Owens & Minor Inc (OMI:NYSE) today announced "preliminary financial results for the second quarter of 2020 that are expected to benefit from improved productivity and increased manufacturing output in response to unprecedented demand for personal protective equipment, an earlier than expected increase in elective procedures across much of the country, favorable product mix, and operating efficiencies."
Owens & Minor advised that for Q2/20 it now expects to report a GAAP net income (loss) per share from continuing operations in the range of ($0.02) to $0.00 and non-GAAP adjusted net income per share in the range of $0.18 to $0.20.
The firm also mentioned that it is revising its forward earnings outlook and that it now expects full-year 2020 adjusted net income of between $0.50 to $0.60 per share on a constant currency basis and adjusted net income of between $1.00 to $1.20 per share. The firm noted that it does not anticipate that foreign currency adjustments will have any material impact on FY/20 adjusted net income per share.
The company stated that it plans to release complete Q2/20 financial results after U.S. markets close for trading on Tuesday, August 4, 2020. The firm advised that later that same day it will host a conference call at 4:30 p.m. EDT to discuss the second quarter results in detail.
Owens & Minor is headquartered in Richmond, Va., and is a global healthcare solutions company. The company employs approximately 15,400 people and markets products and services in 70 around countries. The firm offers a broad spectrum of integrated technologies, products, services and logistical support to healthcare providers and manufacturers across the continuum of care.
Owens & Minor started off the day with a market capitalization of around $500.3 million with approximately 63.01 million shares outstanding and a short interest of about 21.4%. OMI shares opened greater than 29% higher today at $10.28 (+$2.34, +29.47%) over yesterday's $7.94 closing price and reached a new 52-week high price this morning of $15.40. The stock has traded today between $10.16 and $15.40 per share and is currently trading at $14.07 (+$6.13, +77.20%).
[NLINSERT]Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
